Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 1/20 | 0.34 |
| ▸ | DNMT1 | P26358 | 5/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | POLG | P54098 | 1/20 | 0.32 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.32 |
| ▸ | ADK | P55263 | 1/20 | 0.31 |
| ▸ | TK1 | P04183 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL429523 | 0.90 | DNMT1 (0.42) | ALBDNMT1ADRB1DNMT3BTK1 | |
| SCHEMBL429524 | 0.90 | DNMT1 (0.42) | ALBDNMT1ADRB1DNMT3BTK1 | |
| SCHEMBL2611637 | 0.90 | DNMT1 (0.42) | ALBDNMT1ADRB1DNMT3BTK1 | |
| SCHEMBL887459 | 0.90 | DNMT1 (0.42) | ALBDNMT1ADRB1DNMT3BTK1 | |
| SCHEMBL430399 | 0.86 | TOP2A (0.36) | DNMT1ADRB1 | |
| SCHEMBL10080771 | 0.86 | TOP2A (0.36) | DNMT1ADRB1 | |
| SCHEMBL430398 | 0.86 | TOP2A (0.36) | DNMT1ADRB1 | |
| SCHEMBL887464 | 0.86 | TOP2A (0.36) | DNMT1ADRB1 | |
| SCHEMBL2611639 | 0.83 | ALB (0.32) | ALBDNMT1ADRB1 | |
| SCHEMBL19107437 | 0.82 | ALB (0.34) | ALBDNMT1ADRB1POLGDNMT3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160362737-A1 | MODIFIED NUCLEOTIDES | SOLEXA LIMITED (GB) | 2016-12-15 | — | — | US | disclosed |
| US-9388464-B2 | Modified nucleotides | ILLUMINA CAMBRIDGE LIMITED (GB) | 2016-07-12 | — | — | US | disclosed |
| US-20160032378-A1 | MODIFIED NUCLEOTIDES | SOLEXA LIMITED (GB) | 2016-02-04 | — | — | US | disclosed |
| US-9121060-B2 | Modified nucleotides | ILLUMINA CAMBRIDGE LIMITED (GB) | 2015-09-01 | — | — | US | disclosed |
| US-20130197209-A1 | MODIFIED NUCLEOTIDES | ILLUMINA CAMBRIDGE LIMITED (GB) | 2013-08-01 | — | — | US | disclosed |
| US-20120095201-A1 | MODIFIED NUCLEOTIDES | ILLUMINA CAMBRIDGE LIMITED (GB) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362737-A1 | MODIFIED NUCLEOTIDES | ADAR, NT5C2, NSUN2 | ALB 4766/4885DNMT1 235/4885ADRB1 2081/4885 |
| US-20130197209-A1 | MODIFIED NUCLEOTIDES | ADAR, NT5C2, NSUN2 | ALB 4765/4885DNMT1 241/4885ADRB1 2083/4885 |
| US-20120095201-A1 | MODIFIED NUCLEOTIDES | RNMT, NSUN2, NSUN3 | ALB 3428/4885DNMT1 173/4885ADRB1 2971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.